SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: Our finding that the SETD2 deficiency occurs at the post‐translational level, with unchanged mRNA expression, during imatinib resistance in CML provides evidence that in addition to genetic changes, the post‐translational mechanisms also play a vital role in promoting the progression of leukaemia triggered by SETD2 dysregulation.